Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic Disease
Gilead Sciences renewed its five-year collaboration with the World Health Organization to help eliminate visceral leishmaniasis, a fatal parasitic disease. The agreement includes a commitment of $9.2 million in financial support and more than 400,000 vials of AmBisome through 2030, focusing on high-burden countries in East Africa.
Key figures
- Financial support
- $9.2 million
- Product donation vials
- 400,000
- Partnership duration years
- 5
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.